TOP TEN perturbations for 39894_f_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39894_f_at
Selected probe(set): 204520_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39894_f_at (204520_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.982768Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
HCC study 27 (young; validation) / HCC study 27 (elder; validation)
Relative Expression (log2-ratio):2.3932352Number of Samples:21 / 10
Experimental | HCC study 27 (young; validation) |
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a validation cohort. | |
Control | HCC study 27 (elder; validation) |
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort. |
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-2.21877Number of Samples:2 / 10
Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
Control | normal epidermal Langerhans cell sample |
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.0777502Number of Samples:4 / 4
Experimental | R547 study 1 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.0517225Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
oxyphilic adenoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-1.953309Number of Samples:4 / 2
Experimental | oxyphilic adenoma study 1 |
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-1.9377327Number of Samples:4 / 4
Experimental | R547 study 3 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
influenza virus study 11 (A/H5N3) / influenza virus study 9 (A/H5N2)
Relative Expression (log2-ratio):1.9296265Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 9 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):1.9056988Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-1.8208761Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |